WHAT IS CLAIMED IS:

1. A composition of subunit dengue vaccine, comprising:

a fusion protein of truncated NS1 polypeptide consisting of SEQ ID NOs: 5 and truncated NS3c polypeptide consisting of SEQ ID NOs: 6, and optionally together with one or more pharmaceutically acceptable carriers and/or adjuvants.

2. The composition according to claim 1, further comprising a cEDIII polypeptide consisting of SEQ ID NOs: 1 or 4.

3. A use of a fusion protein in the manufacture of a medicament for reducing DENV-induced prolonged bleeding time, wherein the fusion protein is consisted of truncated NS1 polypeptide of SEQ ID NOs: 5 and truncated NS3c polypeptide of SEQ ID NOs: 6 in an order of truncated NS1-truncated NS3c from N-terminus to C-terminus.

4. A use of a fusion protein in the manufacture of a medicament for reducing DENV-induced prolonged bleeding time, wherein the fusion protein is consisted of truncated NS1 polypeptide consisting of SEQ ID NOs: 5, cEDIII polypeptide consisting of SEQ ID NOs: 1 or 4, and truncated NS3c polypeptide consisting of SEQ ID NOs: 6 in an order of truncated NS1-cEDIII-truncated NS3c from N-terminus to C-terminus.